DAFTAR PUSTAKA

Abe, K. *et al.* (2021) 'Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study', *Journal of Diabetes Investigation*, 12(11), pp. 2028–2035. Available at: https://doi.org/10.1111/jdi.13568.

Abraham, A. *et al.* (2018) 'Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies', *European Journal of Neurology*, 25(3), pp. 484–490. Available at: https://doi.org/10.1111/ene.13533.

Ahmad, A. (2016) 'Study of Electrophysiological Changes in Sensory Nerves Among Diabetic Smokers', *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH* [Preprint]. Available at: https://doi.org/10.7860/JCDR/2016/16673.7103.

Albers, J.W. *et al.* (2010) 'Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study', *Diabetes Care*, 33(5), pp. 1090–1096. Available at: https://doi.org/10.2337/dc09-1941.

Andersen, S.T. *et al.* (2018) 'Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark', *Diabetes Care*, 41(5), pp. 1068–1075. Available at: https://doi.org/10.2337/dc17-2062.

Ang, L. *et al.* (2014) 'Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials', *Current Diabetes Reports*, 14(9), p. 528. Available at: https://doi.org/10.1007/s11892-014-0528-7.

Anjana, R.M. *et al.* (2017) 'Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study', *The Lancet Diabetes & Endocrinology*, 5(8), pp. 585–596. Available at: https://doi.org/10.1016/S2213-8587(17)30174-2.

Assunção, A. *et al.* (2020) 'The impact of demographic and clinical characteristics on diabetic painful neuropathy', *Romanian Journal of Internal Medicine*, 58(1), pp. 13–19. Available at: https://doi.org/10.2478/rjim-2019-0019.

Bansal, D. *et al.* (2014) 'Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary

care setting', *Journal of Diabetes Investigation*, 5(6), pp. 714–721. Available at: https://doi.org/10.1111/jdi.12223.

Bansal, V., Kalita, J. and Misra, U.K. (2006) 'Diabetic neuropathy.', *Postgraduate medical journal*, 82(964), pp. 95–100. Available at: https://doi.org/10.1136/pgmj.2005.036137.

Bondar, A. *et al.* (2021) 'Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)', *Experimental and Therapeutic Medicine*, 22(1), p. 690. Available at: https://doi.org/10.3892/etm.2021.10122.

Boulton, A.J.M. *et al.* (2005) 'Diabetic Neuropathies', *Diabetes Care*, 28(4), pp. 956–962. Available at: https://doi.org/10.2337/diacare.28.4.956.

Bril, V. *et al.* (2009) 'Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy', *Diabetic Medicine*, 26(3), pp. 240–246. Available at: https://doi.org/10.1111/j.1464-5491.2009.02667.x.

Bril, V. and Buchanan, R.A. (2004) 'Aldose Reductase Inhibition by AS-3201 in Sural Nerve From Patients With Diabetic Sensorimotor Polyneuropathy', *Diabetes Care*, 27(10), pp. 2369–2375. Available at: https://doi.org/10.2337/diacare.27.10.2369.

Bril, V. and Perkins, B.A. (2002) 'Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy', *Diabetes Care*, 25(11), pp. 2048–2052. Available at: https://doi.org/10.2337/diacare.25.11.2048.

Bromberg, M.B. (2013) 'An Electrodiagnostic Approach to the Evaluation of Peripheral Neuropathies', *Physical Medicine and Rehabilitation Clinics of North America*, 24(1), pp. 153–168. Available at: https://doi.org/10.1016/j.pmr.2012.08.020.

Callaghan, B.C., Cheng, H.T., *et al.* (2012) 'Diabetic neuropathy: clinical manifestations and current treatments', *The Lancet Neurology*, 11(6), pp. 521–534. Available at: https://doi.org/10.1016/S1474-4422(12)70065-0.

Callaghan, B.C., Little, A.A., *et al.* (2012) 'Enhanced glucose control for preventing and treating diabetic neuropathy', *Cochrane Database of Systematic Reviews* [Preprint]. Available at: https://doi.org/10.1002/14651858.CD007543.pub2.

Callaghan, B.C. *et al.* (2014) 'Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy', *JAMA Neurology*, 71(9), p. 1143. Available at: https://doi.org/10.1001/jamaneurol.2014.1279.

Callaghan, B.C. *et al.* (2015) 'The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy', *JAMA Neurology*, 72(12), p. 1510. Available at: https://doi.org/10.1001/jamaneurol.2015.2347.

Callaghan, B.C. *et al.* (2020) 'Diabetic neuropathy: what does the future hold?', *Diabetologia*, 63(5), pp. 891–897. Available at: https://doi.org/10.1007/s00125-020-05085-9.

Callaghan, B.C., Price, R.S. and Feldman, E.L. (2015) 'Distal Symmetric Polyneuropathy', *JAMA*, 314(20), p. 2172. Available at: https://doi.org/10.1001/jama.2015.13611.

Chen, S. and Tseng, C.-H. (2013) 'Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients', *The Review of Diabetic Studies*, 10(2–3), pp. 88–100. Available at: https://doi.org/10.1900/RDS.2013.10.88.

Cheng, C. *et al.* (2015) 'Evidence for Epigenetic Regulation of Gene Expression and Function in Chronic Experimental Diabetic Neuropathy', *Journal of Neuropathology & Experimental Neurology*, 74(8), pp. 804–817. Available at: https://doi.org/10.1097/NEN.0000000000000219.

Cheng, Y. *et al.* (2022) 'Determinants of Diabetic Peripheral Neuropathy and Their Clinical Significance: A Retrospective Cohort Study', *Frontiers in Endocrinology*, 13. Available at: https://doi.org/10.3389/fendo.2022.934020.

Court, F.A. *et al.* (2008) 'Schwann Cell to Axon Transfer of Ribosomes: Toward a Novel Understanding of the Role of Glia in the Nervous System', *The Journal of Neuroscience*, 28(43), pp. 11024–11029. Available at: https://doi.org/10.1523/JNEUROSCI.2429-08.2008.

Dunnigan, S.K. *et al.* (2013) 'Conduction Slowing in Diabetic Sensorimotor Polyneuropathy', *Diabetes Care*, 36(11), pp. 3684–3690. Available at: https://doi.org/10.2337/dc13-0746.

Dyck, P.J. *et al.* (2010) 'Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial', *Muscle & Nerve*, 42(2), pp. 157–164. Available at: https://doi.org/10.1002/mus.21661.

Eid, S. *et al.* (2019) 'New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism', *Diabetologia*, 62(9), pp. 1539–1549. Available at: https://doi.org/10.1007/s00125-019-4959-1.

Fateh, H.R. and Madani, S.P. (2021) 'Role of interdigital sensory nerve

conduction study as a noninvasive approach for early diagnosis of diabetic peripheral neuropathy', *Journal of Diabetes & Metabolic Disorders*, 20(1), pp. 71–75. Available at: https://doi.org/10.1007/s40200-020-00710-1.

Feldman, E.L. *et al.* (2017) 'New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain', *Neuron*, 93(6), pp. 1296–1313. Available at: https://doi.org/10.1016/j.neuron.2017.02.005.

Feldman, E.L. *et al.* (2019) 'Diabetic neuropathy.', *Nature reviews. Disease primers*, 5(1), p. 42. Available at: https://doi.org/10.1038/s41572-019-0097-9.

GRADE Study Research Group *et al.* (2022) 'Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.', *The New England journal of medicine*, 387(12), pp. 1075–1088. Available at: https://doi.org/10.1056/NEJMoa2200436.

Grisold, A., Callaghan, B.C. and Feldman, E.L. (2017) 'Mediators of diabetic neuropathy', *Current Opinion in Endocrinology & Diabetes and Obesity*, 24(2), pp. 103–111. Available at: https://doi.org/10.1097/MED.0000000000000320.

Hashem, M.M. *et al.* (2021) 'The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus', *Scientific Reports*, 11(1), p. 1940. Available at: https://doi.org/10.1038/s41598-021-81631-8.

Hur, J. *et al.* (2016) 'Transcriptional networks of murine diabetic peripheral neuropathy and nephropathy: common and distinct gene expression patterns', *Diabetologia*, 59(6), pp. 1297–1306. Available at: https://doi.org/10.1007/s00125-016-3913-8.

Huynh, W. and Kiernan, M.C. (2011) 'Nerve conduction studies.', *Australian family physician*, 40(9), pp. 693–7.

Hyllienmark, L. *et al.* (2013) 'Early Electrophysiological Abnormalities and Clinical Neuropathy', *Diabetes Care*, 36(10), pp. 3187–3194. Available at: https://doi.org/10.2337/dc12-2226.

Hyllienmark L, Alstrand N, J.B. (2013) 'Early electrophysiological abnormalities and clinical neuropathy: a prospective study in patients with type 1 diabetes', *Diabetes Care*, 36, pp. 3187–3194.

Jin, H.Y. and Park, T.S. (2015) 'Can nerve conduction studies detect earlier and predict clinical diabetic neuropathy?', *Journal of Diabetes Investigation*, 6(1), pp. 18–20. Available at: https://doi.org/10.1111/jdi.12236.

Jun, J.E. *et al.* (2015) 'The association between glycemic variability and

diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes', *Cardiovascular Diabetology*, 14(1), p. 70. Available at: https://doi.org/10.1186/s12933-015-0233-0.

Kaur, S., Pandhi, P. and Dutta, P. (2011) 'Painful diabetic neuropathy: an update.', *Annals of neurosciences*, 18(4), pp. 168–75. Available at: https://doi.org/10.5214/ans.0972-7531.1118409.

Kautzky-Willer, A., Harreiter, J. and Pacini, G. (2016) 'Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus', *Endocrine Reviews*, 37(3), pp. 278–316. Available at: https://doi.org/10.1210/er.2015-1137.

Keane, W.F., Tomassini, J.E. and Neff, D.R. (2011) 'Lipid Abnormalities in Patients with Chronic Kidney Disease', in, pp. 135–142. Available at: https://doi.org/10.1159/000327317.

Kobayashi, M. *et al.* (2017) 'Diabetic polyneuropathy, sensory neurons, nuclear structure and spliceosome alterations: a role for CWC22', *Disease Models & Mechanisms*, 10(3), pp. 215–224. Available at: https://doi.org/10.1242/dmm.028225.

Li, L. *et al.* (2022) 'Impaired Vascular Endothelial Function is Associated with Peripheral Neuropathy in Patients with Type 2 Diabetes', *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, Volume 15, pp. 1437–1449. Available at: https://doi.org/10.2147/DMSO.S352316.

Liu, X. *et al.* (2019) 'The risk factors for diabetic peripheral neuropathy: A meta-analysis', *PLOS ONE*, 14(2), p. e0212574. Available at: https://doi.org/10.1371/journal.pone.0212574.

McGregor, B.A. *et al.* (2018) 'Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy', *Scientific Reports*, 8(1), p. 17678. Available at: https://doi.org/10.1038/s41598-018-36098-5.

Mohseni, S. *et al.* (2017) 'Longitudinal study of neuropathy, microangiopathy, and autophagy in sural nerve: Implications for diabetic neuropathy', *Brain and Behavior*, 7(8), p. e00763. Available at: https://doi.org/10.1002/brb3.763.

Ogilvie, R.P. and Patel, S.R. (2018) 'The Epidemiology of Sleep and Diabetes', *Current Diabetes Reports*, 18(10), p. 82. Available at: https://doi.org/10.1007/s11892-018-1055-8.

Pan, A. *et al.* (2011) 'Rotating Night Shift Work and Risk of Type 2 Diabetes: Two Prospective Cohort Studies in Women', *PLoS Medicine*, 8(12), p. e1001141. Available at:

https://doi.org/10.1371/journal.pmed.1001141.

Pan, S. and Chan, J.R. (2017) 'Regulation and dysregulation of axon infrastructure by myelinating glia', *Journal of Cell Biology*, 216(12), pp. 3903–3916. Available at: https://doi.org/10.1083/jcb.201702150.

Papanas, N. *et al.* (2010) 'The sural sensory/radial motor amplitude ratio for the diagnosis of peripheral neuropathy in type 2 diabetic patients.', *Hippokratia*, 14(3), pp. 198–202.

Peltier, A., Goutman, S.A. and Callaghan, B.C. (2014) 'Painful diabetic neuropathy', *BMJ*, 348(may06 1), pp. g1799–g1799. Available at: https://doi.org/10.1136/bmj.g1799.

Perkins, B.A. *et al.* (2001) 'Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic', *Diabetes Care*, 24(2), pp. 250–256. Available at: https://doi.org/10.2337/diacare.24.2.250.

Perkins BA, Olaleye D, Zinman B, B. V. (2001) 'Simple screening tests for peripheral neuropathy in the diabetes clinic', *Diabetes Care*, 24, pp. 250–256.

Ponirakis, G., Petropoulos, I.N., *et al.* (2019) 'Hypertension Contributes to Neuropathy in Patients With Type 1 Diabetes', *American Journal of Hypertension*, 32(8), pp. 796–803. Available at: https://doi.org/10.1093/ajh/hpz058.

Ponirakis, G., Elhadd, T., *et al.* (2019) 'Prevalence and risk factors for painful diabetic neuropathy in secondary healthcare in Qatar', *Journal of Diabetes Investigation*, 10(6), pp. 1558–1564. Available at: https://doi.org/10.1111/jdi.13037.

Pop-Busui, R. *et al.* (2010) 'DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History', *Current Diabetes Reports*, 10(4), pp. 276–282. Available at: https://doi.org/10.1007/s11892-010-0120-8.

Pop-Busui, R. *et al.* (2017) 'Diabetic Neuropathy: A Position Statement by the American Diabetes Association', *Diabetes Care*, 40(1), pp. 136–154. Available at: https://doi.org/10.2337/dc16-2042.

Pourkazemi, A. *et al.* (2020) 'Diabetic foot care: knowledge and practice', *BMC Endocrine Disorders*, 20(1), p. 40. Available at: https://doi.org/10.1186/s12902-020-0512-y.

Rathi, N., Taksande, B. and Kumar, S. (2019) 'Nerve Conduction Studies of Peripheral Motor and Sensory Nerves in the Subjects With Prediabetes', *Journal of Endocrinology and Metabolism*, 9(5), pp. 147–150. Available at: https://doi.org/10.14740/jem602.

Román-Pintos, L.M. *et al.* (2016) 'Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function', *Journal of Diabetes Research*, 2016, pp. 1–16. Available at: https://doi.org/10.1155/2016/3425617.

Rumora, A.E. *et al.* (2019) 'The Divergent Roles of Dietary Saturated and Monounsaturated Fatty Acids on Nerve Function in Murine Models of Obesity', *The Journal of Neuroscience*, 39(19), pp. 3770–3781. Available at: https://doi.org/10.1523/JNEUROSCI.3173-18.2019.

Saini, D., Kochar, A. and Poonia, R. (2021) 'Clinical correlation of diabetic retinopathy with nephropathy and neuropathy', *Indian Journal of Ophthalmology*, 69(11), p. 3364. Available at: https://doi.org/10.4103/ijo.IJO_1237_21.

Schneider, A.L.C. *et al.* (2013) 'Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study', *Diabetic Medicine*, 30(8), pp. 926–933. Available at: https://doi.org/10.1111/dme.12187.

Sekiguchi, K. *et al.* (2019) 'Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan', *Journal of Diabetes Investigation*, 10(2), pp. 466–474. Available at: https://doi.org/10.1111/jdi.12890.

Shaw, J.E., Sicree, R.A. and Zimmet, P.Z. (2010) 'Global estimates of the prevalence of diabetes for 2010 and 2030', *Diabetes Research and Clinical Practice*, 87(1), pp. 4–14. Available at: https://doi.org/10.1016/j.diabres.2009.10.007.

Su, J. *et al.* (2018) 'HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients', *Cardiovascular Diabetology*, 17(1), p. 47. Available at: https://doi.org/10.1186/s12933-018-0693-0.

Tabish, S.A. (2007) 'Is Diabetes Becoming the Biggest Epidemic of the Twenty-first Century?', *International journal of health sciences*, 1(2), pp. V–VIII.

Veresiu, A.I. *et al.* (2015) 'Detection of undisclosed neuropathy and assessment of its impact on quality of life: a survey in 25,000 Romanian patients with diabetes', *Journal of Diabetes and its Complications*, 29(5), pp. 644–649. Available at: https://doi.org/10.1016/j.jdiacomp.2015.04.001.

Vincent, A.M. *et al.* (2009) 'Dyslipidemia-Induced Neuropathy in Mice', *Diabetes*, 58(10), pp. 2376–2385. Available at: https://doi.org/10.2337/db09-0047.

Vinik, A.I. (2004) ‘Advances in diabetes for the millennium: new treatments for diabetic neuropathies.’, *MedGenMed : Medscape general medicine*, 6(3 Suppl), p. 13.

Visser, N.A. *et al.* (2015) ‘Incidence of polyneuropathy in Utrecht, the Netherlands’, *Neurology*, 84(3), pp. 259–264. Available at: https://doi.org/10.1212/WNL.0000000000001160.

Wang, Limin *et al.* (2017) ‘Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013’, *JAMA*, 317(24), p. 2515. Available at: https://doi.org/10.1001/jama.2017.7596.

Weisman, A. *et al.* (2013) ‘Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters’, *PLoS ONE*, 8(3), p. e58783. Available at: https://doi.org/10.1371/journal.pone.0058783.

Whiting, D.R. *et al.* (2011) ‘IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030’, *Diabetes Research and Clinical Practice*, 94(3), pp. 311–321. Available at: https://doi.org/10.1016/j.diabres.2011.10.029.

Wilbourn, A.J. (2002) ‘Nerve conduction studies’, *Neurologic Clinics*, 20(2), pp. 305–338. Available at: https://doi.org/10.1016/S0733-8619(01)00003-2.

Won, J.C. and Park, T.S. (2016) ‘Recent Advances in Diagnostic Strategies for Diabetic Peripheral Neuropathy’, *Endocrinology and Metabolism*, 31(2), p. 230. Available at: https://doi.org/10.3803/EnM.2016.31.2.230.

LAMPIRAN

FORMULIR PERSETUJUAN SETELAH PENJELASAN

Saya yang bertandatangan di bawah ini:
Nama : .....
Umur : .....
Alamat : .....
No. HP : .....
Telah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan prosedur pada penelitian dengan judul **HUBUNGAN PARAMETER NERVE CONDUCTION STUDIES (NCS) DAN DERAJAT KEPARAHAN NEUROPATI DIABETIK DENGAN TORONTO CLINICAL NEUROPATHY SCORE (TCNS) DI RUMAH SAKIT WAHIDIN SUDIROHUSODO.** Saya menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.
Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini. Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian terjamin dan dengan ini menyetujui semua data yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan. Dengan membubuhkan tanda tangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

Nama		**Tanda tangan**	**Tgl/Bln/Thn**
Responden	……	……	……
Saksi 1	……	……	……
Saksi 2	……	……	……

Penanggung jawab penelitian:
Nama : dr. Teuku Rahmat Irdiansyah
Alamat : Jalan mesjid Al-Iklas komplek perumahan dosen Unhas, Makassar
Telepon (HP) : 085275977076

Penanggung jawab medis:
Nama : dr.Muh. Iqbal Basri, M.kes, Sp.S(K)
Telepon (HP) : 08124161449

FORMULIR NCS (NERVE CONDUCTION STUDIES)

Indikator	Kanan	Kiri	Nilai Normal
Tibialis (motorik)			
Latensi distal (ms)			≤5,8
Amplitudo (mV)			≥4,0
NCV* (m/s)			≥41
Peroneus (motorik)			
Latensi distal (ms)			≤6,5
Amplitudo (mV)			≥2,0
NCV* (m/s)			≥44
Suralis (sensorik)			
Latensi puncak (ms)			≤4,4
Amplitudo (µV)			≥6
NCV* (m/s)			≥40
Peroneus superficialis (sensorik)			
Latensi puncak (ms)			≤4,4
Amplitudo (µV)			≥6
NCV* (m/s)			≥40

NCV: Nerve Conduction Velocity

Tipe neuropati berdasarkan jenis saraf : Motorik/sensorik/sensorimotor

Tipe neuropati berdasarkan patogenesis : Demielinasi/aksonal/campuran

BDC : 0/1/2/3/4

No	Nama	Tgl Lahir	Umur	Jenis Kelamin	Pekerjaan	Tipe DM	Durasi DM	Terapi DM	HT	Dislipid	Merokok	HbA1c
1	St	25/05/1965	57	Perempuan	IRT	2	10	Insulin	Ya	Ya	Tidak	14
2	Ha	31-Dec-64	57	Perempuan	ASN	2	10	OAD + insulin	Tidak	Ya	Tidak	11,3
3	Sy	1-Jan-65	57	Laki-laki	SWASTA (Op	2	6	OAD + insulin	Tidak	Tidak	Tidak	6,7
4	In	13/11/1966	56	Perempuan	Penjahit	2	10	OAD	Ya	Ya	Tidak	6,1
5	Ik	19-Aug-84	38	Laki-laki	ASN	2	5	OAD	Ya	Ya	Tidak	8,2
6	Ka	11-Jan-78	44	Perempuan	IRT	2	1	OAD	Ya	Ya	Tidak	8,2
7	An	31-Dec-60	61	Laki-laki	Pensiunan	2	10	OAD	Tidak	Tidak	Tidak	10,8
8	Mu	26/11/1964	58	Perempuan	ASN (Dosen)	2	1	OAD	Ya	Ya	Tidak	10,4
9	Da	7-Sep-69	53	Laki-laki	Swasta	2	4	OAD	Tidak	Tidak	dah berhenti	7,9
10	Ma	18/03/1975	47	Perempuan	IRT	2	5	OAD	Tidak	Tidak	Tidak	7,8
11	Moe	4-Feb-55	64	Laki-laki	Pensiunan	2	7	OAD	Ya	Ya	dah berhenti	7,9
12	Her	10/10/1965	57	Perempuan	Guru	2	6	OAD	Tidak	Ya	Tidak	12
13	Na	31/12/1968	53	Perempuan	Guru	2	10	OAD	Ya	Tidak	Tidak	7,3
14	Muh	26-May-75	47	Laki-laki	Swasta	2	12	Insulin	Tidak	Ya	Tidak	14,3
15	Ra	18-Jun-56	66	Laki-laki	Pensiunan	2	14	Insulin	Tidak	Tidak	sdh berhenti	10,5
16	HS	2-Aug-68	54	Perempuan	IRT	2	12	Insulin	Ya	Tidak	Tidak	9,7
17	AS	15/08/1963	59	Laki-laki	Pensiunan	2	1	Insulin	Tidak	Tidak	Tidak	9,8
18	Hu	25/05/1961	61	Laki-laki	Sopir	2	1	OAD	Ya	Tidak	dah berhenti	11,28
19	FM	24/12/1960	62	Perempuan	IRT	2	1	OAD	Ya	Tidak	Tidak	11,5
20	Hw	04/04/1963	59	Perempuan	Perawat	2	1	OAD	Tidak	Tidak	Tidak	8,2
21	Naz	18/03/1958	64	Laki-laki	Pensiunan	2	1	OAD	Ya	Tidak	Tidak	8
22	Mah	17-Jun-69	53	Laki-laki	ASN	2	12	Insulin	Tidak	Ya	Tidak	7,2
23	Has	15/04/1978	44	Perempuan	CS	2	1	OAD	Tidak	Tidak	Tidak	7,8
24	RS	30/04/1969	53	Perempuan	PNS	2	3	Insulin	Ya	Ya	Tidak	13
25	Si	22/11/1965	57	Laki-laki	Swasta	2	8	OAD	Tidak	Ya	7 th berhenti	6,6
26	Hf	05/05/1959	64	Laki-laki	Pertambang	2	12	Insulin	Ya	Ya	0 th berhenti	6,5
27	FR	05/01/1900	53	Perempuan	Dosen	2	17	Insulin + OAD	Tidak	Tidak	Tidak	10,1
28	RA	20-Dec-71	51	Laki-laki	TNI	2	4	OAD + insulin	Ya	Ya	Ya	7,5
29	Ts	20-Jun-73	49	Laki-laki	Buruh	2	2	OAD	Tidak	Tidak	Tidak	11,3
30	HMY	16-Dec-64	58	Laki-laki	Swasta	2	23	Insulin	Ya	Tidak	Ya	9,5
31	Ro	29-Jan-61	62	Perempuan	IRT	2	15	OAD + insulin	Ya	Ya	Tidak	10,0
32	Be	17-Sep-79	43	Perempuan	ASN	2	5	Insulin	Tidak	Ya	Tidak	11,5
33	Mmp	26-Mar-70	53	Perempuan	ASN	2	2	Insulin	Tidak	Ya	Tidak	6,7
34	Asf	20-Sep-75	47	Perempuan	ASN	2	4	OAD	Tidak	Tidak	Tidak	10,6
35	Dl	7-Sep-69	53	Laki-laki	Swasta	2	4	OAD	Tidak	Tidak	Ya	7,9
36	Wnh	28-Feb-66	57	Laki-laki	ASN	2	19	Insulin	Tidak	Ya	Tidak	9,2

Tib LD Kanan	Tib LD Kiri	Tib Amp Kanan	Tib Amp Kiri	Tib NCV Kanan	Tib NCV Kiri	Pero LD Kanan	Pero LD Kiri	Pero Amp Kanan	Pero Amp Kiri	Pero NCV Kanan	Pero NCV Kiri	Sur LP Kanan	Sur LP Kiri	Sur Amp Kanan	Sur Amp Kiri	Sur NCV Kanan	Sur NCV Kiri	Pero Sup LP Kanan	Pero Sup LP Kiri	Pero Sup Amp Kanan	Pero Sup Amp Kiri	Pero Sup NCV Kanan	Pero Sup NCV Kiri
3,8	3,8	1	6,8	33	29	3,4	4,1	5,5	4,6	47	51	3,6	3,1	7,5	5,5	47	61	3,5	4	11,4	9,5	48	39
4,3	4,4	5,2	6,1	38	38	4,1	4,9	1,4	0,3	40	32	17,6	5,7	1,7	2,0	9	140	NR	NR	NR	NR	NR	NR
4,1	3,8	1,9	3,2	36	40	5,2	7	0,3	0,5	26	35	4,8	3,7	7,6	5,3	37	46	NR	4,2	NR	3,9	NR	39
5,5	3,4	7,4	6,3	53	36	4	4,3	3,5	2	43	36	3,2	2,9	8	9,2	56	64	2	2,5	9,3	5	67	78
3,8	4,1	7,7	5,6	44	44	5,9	7,3	2,0	2,1	44	44	3,9	3,9	6,6	6,3	41	42	3,1	3,9	7,9	6,5	61	50
5,9	3,4	16,2	15,4	42	45	4	3,8	2,5	0,5	45	50	3,8	3,3	9,4	9,8	44	54	3,6	3,3	12,6	7,5	50	56
5,9	3,9	1,8	1,6	31	37	7,5	3,5	0,1	0,5	44	32	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
3,7	3,9	8	5	37	38	4,4	4	1,6	1	39	36	4	4	8,2	3,1	45	42	NR	NR	NR	NR	NR	NR
3,7	3,4	7,3	10,1	41	43	5,4	5,0	1,6	0,0	47	0	NR	NR	NR	NR	NR	NR	3,2	NR	19,6	NR	45	NR
3,1	3,1	12,4	16,1	46	49	3,8	3,5	1,9	2	29	45	2,8	2,6	14,5	36,1	45	76	3,8	3,5	1,9	2	29	45
3,8	2,7	4	3,5	44	31	5,2	3,7	0,9	2,3	39	33	NR	NR	NR	NR	NR	NR	3,3	2,8	12	3,4	52	70
5,3	4,8	8,9	8,6	33	34	5,4	6,3	3,1	2,3	35	31	4,1	3	6,5	7,2	40	56	NR	8,4	NR	20,2	NR	56
2,6	2,8	8,2	8,1	50	49	3	3,8	2,7	1,8	54	53	3,1	3,5	11,5	12	56	52	2,6	2,8	9	9,7	55	64
4,0	3,7	2,8	5,2	29	34	5,8	6,1	1,4	0,5	38	28	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
7,7	4,1	8,5	11,0	38	46	5,5	4,4	0,3	1,8	41	48	NR	3,2	NR	4,4	NR	44	NR	3,6	NR	8,2	NR	42
4,4	3,2	4,9	3,7	32	35	3,7	5,7	1,9	1	40	37	3,6	3,4	2,3	2,3	50	54	2,9	2,9	6,2	2,8	61	67
3,9	3,5	8,2	15	47	35	4,5	4,8	2	1,5	42	49	3,3	3,6	12	16,8	52	50	3,3	3,5	9,2	17,1	52	56
4,6	5	9,5	6,6	35	39	4,8	5,5	1,8	1,8	39	38	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
3,4	3,4	6,1	7,1	40	40	4,8	4,1	1,6	2,8	41	40	4,8	4,3	5,4	4,4	39	42	4,8	4,1	1,6	2,8	41	40
3,3	4,5	7,2	13,5	43	41	4,6	4,8	3,7	3,5	53	53	3	2,9	43,6	68,9	47	48	2,6	2,1	8,6	8,6	54	52
2,8	2,7	16,7	16,2	58	50	2,8	2,7	2	1,4	59	54	2,7	2,8	2	1,4	67	70	2,7	2,8	9,3	7,5	67	67
4	4,7	3,8	5,6	42	50	4,1	4,2	1,5	0,9	47	47	NR	2,8	NR	5,3	NR	50	NR	NR	NR	NR	NR	NR
3	3,4	20,2	18,6	49	47	4,4	4,2	4	3,4	50	54	2,4	2,4	18,1	17,8	58	58	2,2	2,5	19,8	15,3	64	56
5,5	5,9	9,3	10,1	35	39	4,5	5,9	0,6	1,9	29	45	5	4,6	11,5	16	34	38	2,7	3,5	38,2	17,3	34	38
3	3	9,5	9,4	55	52	3,4	3,3	4,4	3,3	57	59	2,6	2,3	13,2	16,4	54	61	2,5	1,8	11,7	11,4	56	78
4,5	5,9	9,2	8,3	38	51	NR	NR	NR	NR	NR	NR	0,3	2,7	3,8	10,2	50	52	NR	NR	NR	NR	NR	NR
NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	1,5	NR	5,5	NR	93
3,4	3,4	11,1	9,6	38	38	4,2	4,5	3,4	2,7	40	40	3,6	3,7	8,6	4,2	47	45	3,9	1,9	7,4	7,4	42	108
6,4	3,7	1,0	8,5	46	37	5,2	7,3	0,5	0,3	42	36	20,0	20,0	0,0	0,0	0	0	20,0	20,0	0,0	0,0	0	0
5,8	10,1	0,2	0,1	31	42	13,8	50,0	0,1	0,0	126	0	20,0	20,0	0,0	0,0	0	0	20,0	20,0	0,0	0,0	0	0
4,1	3,8	9,5	9,0	39	37	4,5	4,6	2,4	3,0	39	41	3,4	20,0	8,4	0,0	39	0	3,0	20,0	9,6	0,0	55	0
2,7	3,0	9,9	14,0	40	45	4,2	3,8	3,7	2,4	44	40	2,7	3,4	6,6	6,0	74	50	2,0	2,1	3,5	4,8	60	63
2,9	3,4	6,7	6,9	42	45	3,4	3,8	0,6	0,8	43	44	2,7	6,6	16,9	13,7	93	22	20,0	20,0	0,0	0,0	0	0
3,8	3,6	11,6	9,1	50	52	5,0	4,6	2,5	1,8	47	46	4,1	3,2	7,6	6,4	40	48	3,3	3,4	7,4	9,2	57	50
3,7	3,4	7,3	10,1	41	43	5,4	50,0	1,6	0,0	47	0	20,0	20,0	0,0	0,0	0	0	3,2	20,0	19,6	0,0	45	0
3,4	3,6	10,4	8,6	42	43	4,3	4,5	4,1	2,1	44	46	20,0	20,0	0,0	0,0	0	0	20,0	20,0	0,0	0,0	0	0

Nyeri kaki	Kebas	kesemutan	kelemahan	ataxia	gejala sensoris upper limb	Total skor gejala	Tes Tusuk / Pin Prick	Tes temperatur	Monofilamen	Vibration	tes Proprioseptif	Total skor sensorik	knee refleks	Ankle Refleks	Total skor reflek	TOTAL TORONTO	TORONTO	DSPN
1	1	1	1	0	0	4	0	0	0	1	0	1	1	1	4	9	Moderate	Positif
1,0	1,0	1,0	0,0	1,0	0,0	4	1,0	1,0	1,0	1,0	0,0	4	1,0	2,0	6	14	Severe	Positif
1	1	1	1	0	0	4	1	1	1	1	0	4	1	1	4	12	Severe	Positif
0	1	0	0	1	0	2	1	1	1	1	0	4	1	1	4	10	Moderate	Positif
1,0	1,0	1,0	0,0	0,0	0,0	3	1,0	0,0	1,0	1,0	0,0	3	1,0	1,0	4	10	Moderate	Positif
1	1	1	1	1	1	6	1	0	1	1	0	3	1	1	4	13	Severe	Positif
1,0	1,0	1,0	1,0	1,0	0,0	5	1,0	1,0	1,0	1,0	0,0	4	1,0	2,0	6	15	Severe	Positif
0	1	1	0	0	0	2	1	0	1	1	0	3	2	2	8	13	Severe	Positif
0,0	1,0	1,0	1,0	1,0	1,0	5	1,0	1,0	1,0	1,0	0,0	4	2,0	2,0	8	17	Severe	Positif
1	1	1	1	0	1	5	1	1	0	1	0	3	1	1	4	12	Severe	Positif
0,0	1,0	1,0	1,0	1,0	1,0	5	1,0	1	1,0	0,0	0,0	3	2,0	2,0	8	16	Severe	Positif
1	1	1	1	1	1	6	1	0	0	1	0	2	1	1	4	12	Severe	Positif
0,0	0,0	0,0	0,0	0,0	0,0	0	1,0	1,0	1,0	1,0	0,0	4	0,0	0,0	0	4	No Neuropath	Negatif
1	1	1	1	0	0	4	1	1	1	1	0	4	2	2	8	16	Severe	Positif
0,0	1,0	1,0	0,0	0,0	1,0	3	1,0	1,0	1,0	1,0	0,0	4	1,0	1,0	4	11	Moderate	Positif
1	1	1	0	0	1	4	1	1	1	1	1	5	1	1	4	13	Severe	Positif
1,0	1,0	1,0	1,0	0,0	1,0	5	0,0	1,0	1,0	1,0	0,0	3	1,0	1,0	4	12	Severe	Positif
1	1	0	0	1	0	3	0	1	1	1	0	3	2	2	8	14	Severe	Positif
0,0	1,0	1,0	0,0	0,0	0,0	2	1,0	0,0	1,0	1,0	0,0	3	2,0	2,0	8	13	Severe	Positif
0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	No Neuropath	Negatif
0,0	1,0	1,0	1,0	0,0	1,0	4	1,0	1,0	1,0	1,0	0,0	4	1,0	0,0	2	10	Moderate	Positif
0	1	0	1	0	0	2	1	0	1	1	0	3	1	1	4	9	Moderate	Positif
1,0	0,0	0,0	1,0	0,0	0,0	2	1,0	1,0	1,0	1,0	0,0	4	1,0	1,0	4	10	Moderate	Positif
1	1	1	1	1	0	5	1	0	1	1	0	3	1	1	4	12	Severe	Positif
1,0	1,0	1,0	1,0	0,0	0,0	4	1,0	0,0	1,0	1,0	0,0	3	0,0	0,0	0	7	Mild	Positif
0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	No Neuropath	Negatif
1,0	1,0	0,0	1,0	1,0	0,0	4	1,0	1,0	1,0	1,0	1,0	5	2,0	2,0	8	17	Severe	Positif
1,0	1,0	1,0	0,0	0,0	0,0	3	1,0	0,0	1,0	1,0	0,0	3	1,0	1,0	4	10	Moderate	Positif
1,0	1,0	0,0	1,0	1,0	0,0	4	1,0	1,0	1,0	1,0	1,0	5	2,0	2,0	8	17	Severe	Positif
0,0	1,0	1,0	0,0	0,0	1,0	3	1,0	1,0	1,0	1,0	0,0	4	1,0	1,0	4	11	Moderate	Positif
1	1	1	0	0	1	4	1	1	1	1	1	5	1	1	4	13	Severe	Positif
1	1	1	0	0	1	4	1	1	1	1	1	5	1	1	4	13	Severe	Positif
1	1	1	0	0	1	4	1	1	1	1	1	5	1	1	4	13	Severe	Positif
0	1	0	1	0	0	2	1	0	1	1	0	3	1	1	4	9	Moderate	Negatif
0	1	0	1	0	0	2	1	0	1	1	0	3	1	1	4	9	Moderate	Positif
0	1	0	1	0	0	2	1	0	1	1	0	3	1	1	4	9	Moderate	Positif

Raw data

Frequencies

Notes

Output Created		05-JUN-2023 13:09:52
Comments		
Input	Data	D:\Office\Statistics\Data dr Rahmat.sav
	Active Dataset	DataSet25
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	36
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics are based on all cases with valid data.
Syntax		FREQUENCIES VARIABLES=Kat_Usia JK Pendidikan Pekerjaan Kat_Durasi Berobat Tatalaksana HT Dislipid Merokok Kat_HbA1c Kategori /ORDER=ANALYSIS.
Resources	Processor Time	00:00:00.02
	Elapsed Time	00:00:00.02

[DataSet25] D:\Office\Statistics\Data dr Rahmat.sav

Statistics

	Kat_Usia	JK	Pendidikan	Pekerjaan	Kat_Durasi	Berobat	Tatalaksana	HT	Dislipid	Merokok	Kat_HbA1c	Kategori
N Valid	36	36	36	36	36	36	36	36	36	36	36	36
Missing	0	0	0	0	0	0	0	0	0	0	0	0

Frequency Table

Kat_Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	31-40 tahun	1	2.8	2.8	2.8
	41-50 tahun	7	19.4	19.4	22.2
	51-60 tahun	20	55.6	55.6	77.8
	61-70 tahun	8	22.2	22.2	100.0
	Total	36	100.0	100.0	

JK

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	18	50.0	50.0	50.0
	Perempuan	18	50.0	50.0	100.0
	Total	36	100.0	100.0	

Pendidikan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	SD	2	5.6	5.6	5.6
	SMP	2	5.6	5.6	11.1
	SMA	8	22.2	22.2	33.3
	D3	1	2.8	2.8	36.1
	S1	11	30.6	30.6	66.7
	S2	6	16.7	16.7	83.3
	S3	6	16.7	16.7	100.0
	Total	36	100.0	100.0	

Pekerjaan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Bekerja	25	69.4	69.4	69.4
	Tidak bekerja	11	30.6	30.6	100.0
	Total	36	100.0	100.0	

Kat_Durasi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	> 5 tahun	21	58.3	58.3	58.3
	< 5 tahun	15	41.7	41.7	100.0
	Total	36	100.0	100.0	

Berobat

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	32	88.9	88.9	88.9
	Tidak	4	11.1	11.1	100.0
	Total	36	100.0	100.0	

Tatalaksana

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	OAD	19	52.8	52.8	52.8
	Insulin	12	33.3	33.3	86.1
	OAD + Insulin	5	13.9	13.9	100.0
	Total	36	100.0	100.0	

HT

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	16	44.4	44.4	44.4
	Tidak	20	55.6	55.6	100.0
	Total	36	100.0	100.0	

Dislipid

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	18	50.0	50.0	50.0
	Tidak	18	50.0	50.0	100.0
	Total	36	100.0	100.0	

Merokok

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	3	8.3	8.3	8.3
	Tidak	33	91.7	91.7	100.0
	Total	36	100.0	100.0	

Kat_HbA1c

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 7	5	13.9	13.9	13.9
	> 7	31	86.1	86.1	100.0
	Total	36	100.0	100.0	

Kategori

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No Neuropath	3	8.3	8.3	8.3
	Mild	1	2.8	2.8	11.1
	Moderate	12	33.3	33.3	44.4
	Severe	20	55.6	55.6	100.0
	Total	36	100.0	100.0	

Means

Notes

Output Created		05-JUN-2023 13:10:18
Comments		
Input	Data	D:\Office\Statistics\Data dr Rahmat.sav
	Active Dataset	DataSet25
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	36
Missing Value Handling	Definition of Missing	For each dependent variable in a table, user-defined missing values for the dependent and all grouping variables are treated as missing.
	Cases Used	Cases used for each table have no missing values in any independent variable, and not all dependent variables have missing values.
Syntax		MEANS TABLES=Usia Durasi HbA1c Tib_Amp_Kanan Tib_Amp_Kiri Sur_Amp_Kanan Sur_Amp_Kiri Total /CELLS=MEAN STDDEV MEDIAN MIN MAX.
Resources	Processor Time	00:00:00.00
	Elapsed Time	00:00:00.01

Case Processing Summary

	Cases					
	Included		Excluded		Total	
	N	Percent	N	Percent	N	Percent
Usia	36	100.0%	0	0.0%	36	100.0%
Durasi	36	100.0%	0	0.0%	36	100.0%
HbA1c	36	100.0%	0	0.0%	36	100.0%
Tib_Amp_Kanan	36	100.0%	0	0.0%	36	100.0%
Tib_Amp_Kiri	36	100.0%	0	0.0%	36	100.0%

Sur_Amp_Kanan	36	100.0%	0	0.0%	36	100.0%
Sur_Amp_Kiri	36	100.0%	0	0.0%	36	100.0%
Total	36	100.0%	0	0.0%	36	100.0%

Report

	Usia	Durasi	HbA1c	Tib_Amp_Kanan	Tib_Amp_Kiri	Sur_Amp_Kanan	Sur_Amp_Kiri	Total
Mean	54.7500	7.1944	9.3689	7.6000	8.4056	6.7083	8.0750	11.3056
Std. Deviation	6.66494	5.76105	2.16412	4.57421	4.50003	8.29483	12.84591	3.82338
Median	56.5000	5.5000	9.3500	7.8500	8.4000	6.5500	4.8500	12.0000
Minimum	38.00	1.00	6.10	.00	.00	.00	.00	1.00
Maximum	66.00	23.00	14.30	20.20	18.60	43.60	68.90	17.00

Explore

Notes

Output Created		05-JUN-2023 13:10:33
Comments		
Input	Data	D:\Office\Statistics\Data dr Rahmat.sav
	Active Dataset	DataSet25
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	36
Missing Value Handling	Definition of Missing	User-defined missing values for dependent variables are treated as missing.

	Cases Used	Statistics are based on cases with no missing values for any dependent variable or factor used.
Syntax		EXAMINE VARIABLES=Tib_Amp_Kanan Tib_Amp_Kiri Sur_Amp_Kanan Sur_Amp_Kiri Total /PLOT BOXPLOT STEMLEAF NPPLOT /COMPARE GROUPS /STATISTICS DESCRIPTIVES /CINTERVAL 95 /MISSING LISTWISE /NOTOTAL.
Resources	Processor Time	00:00:01.08
	Elapsed Time	00:00:01.49

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Tib_Amp_Kanan	36	100.0%	0	0.0%	36	100.0%
Tib_Amp_Kiri	36	100.0%	0	0.0%	36	100.0%
Sur_Amp_Kanan	36	100.0%	0	0.0%	36	100.0%
Sur_Amp_Kiri	36	100.0%	0	0.0%	36	100.0%
Total	36	100.0%	0	0.0%	36	100.0%

Descriptives

			Statistic	Std. Error
Tib_Amp_Kanan	Mean		7.6000	.76237
	95% Confidence Interval for Mean	Lower Bound	6.0523	
		Upper Bound	9.1477	
	5% Trimmed Mean		7.4037	
	Median		7.8500	
	Variance		20.923	
	Std. Deviation		4.57421	
	Minimum		.00	

	Maximum		20.20	
	Range		20.20	
	Interquartile Range		5.28	
	Skewness		.514	.393
	Kurtosis		.748	.768
Tib_Amp_Kiri	Mean		8.4056	.75000
	95% Confidence Interval for Mean	Lower Bound	6.8830	
		Upper Bound	9.9281	
	5% Trimmed Mean		8.3630	
	Median		8.4000	
	Variance		20.250	
	Std. Deviation		4.50003	
	Minimum		.00	
	Maximum		18.60	
	Range		18.60	
	Interquartile Range		4.50	
	Skewness		.319	.393
	Kurtosis		-.120	.768
Sur_Amp_Kanan	Mean		6.7083	1.38247
	95% Confidence Interval for Mean	Lower Bound	3.9018	
		Upper Bound	9.5149	
	5% Trimmed Mean		5.6611	
	Median		6.5500	
	Variance		68.804	
	Std. Deviation		8.29483	
	Minimum		.00	
	Maximum		43.60	
	Range		43.60	
	Interquartile Range		9.20	
	Skewness		2.647	.393
	Kurtosis		10.433	.768
Sur_Amp_Kiri	Mean		8.0750	2.14098
	95% Confidence Interval for Mean	Lower Bound	3.7286	
		Upper Bound	12.4214	
	5% Trimmed Mean		5.9543	
	Median		4.8500	
	Variance		165.017	
	Std. Deviation		12.84591	
	Minimum		.00	

	Maximum		68.90	
	Range		68.90	
	Interquartile Range		10.10	
	Skewness		3.469	.393
	Kurtosis		14.639	.768
Total	Mean		11.3056	.63723
	95% Confidence Interval for Mean	Lower Bound	10.0119	
		Upper Bound	12.5992	
	5% Trimmed Mean		11.5617	
	Median		12.0000	
	Variance		14.618	
	Std. Deviation		3.82338	
	Minimum		1.00	
	Maximum		17.00	
	Range		16.00	
	Interquartile Range		3.75	
	Skewness		-.999	.393
	Kurtosis		1.547	.768

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Tib_Amp_Kanan	.117	36	.200*	.952	36	.122
Tib_Amp_Kiri	.131	36	.122	.970	36	.430
Sur_Amp_Kanan	.209	36	.000	.731	36	.000
Sur_Amp_Kiri	.265	36	.000	.607	36	.000
Total	.162	36	.018	.910	36	.006

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tib_Amp_Kanan

```
Tib_Amp_Kanan Stem-and-Leaf Plot

 Frequency    Stem &  Leaf

     6.00         0 .  001111
     2.00         0 .  23
     3.00         0 .  445
     7.00         0 .  6677777
    11.00         0 .  88888999999
     3.00         1 .  011
     1.00         1 .  2
      .00         1 .
     2.00         1 .  66
     1.00 Extremes    (>=20)

 Stem width:     10.00
 Each leaf:        1 case(s)
```




Detrended Normal Q-Q Plot of Tib_Amp_Kanan
Dev from Normal
1.00
0.75
0.50
0.25
0.00
-0.25
0
5
10
15
20
25
Observed Value


25
20
15
10
5
0
1
Tib_Amp_Kanan

Tib_Amp_Kiri

```
Tib_Amp_Kiri Stem-and-Leaf Plot

 Frequency    Stem &  Leaf

     3.00         0 .  001
     3.00         0 .  333
     4.00         0 .  5555
     6.00         0 .  666667
     9.00         0 .  888889999
     4.00         1 .  0001
     1.00         1 .  3
     3.00         1 .  455
     2.00         1 .  66
     1.00 Extremes    (>=19)

 Stem width:     10.00
 Each leaf:        1 case(s)
```







Sur_Amp_Kanan

Sur_Amp_Kanan Stem-and-Leaf Plot

```
 Frequency    Stem &  Leaf

    13.00        0 .  0000000000001
     3.00        0 .  223
     1.00        0 .  5
     6.00        0 .  666777
     5.00        0 .  88889
     2.00        1 .  11
     2.00        1 .  23
     1.00        1 .  4
     1.00        1 .  6
     1.00        1 .  8
     1.00 Extremes    (>=44)

 Stem width:     10.00
 Each leaf:       1 case(s)
```




Detrended Normal Q-Q Plot of Sur_Amp_Kanan
Dev from Normal
3
2
1
0
-1
0
10
20
30
40
50
Observed Value


50
40
30
20
10
0
4
Sur_Amp_Kanan

Sur_Amp_Kiri

```
Sur_Amp_Kiri Stem-and-Leaf Plot

 Frequency    Stem &  Leaf

    12.00         0 .  000000000001
     3.00         0 .  223
     6.00         0 .  444555
     4.00         0 .  6667
     2.00         0 .  99
     1.00         1 .  0
     2.00         1 .  23
      .00         1 .
     4.00         1 .  6667
     2.00 Extremes    (>=36)

 Stem width:     10.00
 Each leaf:        1 case(s)
```




Detrended Normal Q-Q Plot of Sur_Amp_Kiri
Dev from Normal
3
2
1
0
-1
0
20
40
60
Observed Value


4
16
60
40
20
0
Sur_Amp_Kiri

Total

Total Stem-and-Leaf Plot

```
 Frequency    Stem &  Leaf

     3.00 Extremes    (=<4.0)
     1.00         7 .  0
      .00         8 .
     5.00         9 .  00000
     5.00        10 .  00000
     2.00        11 .  00
     5.00        12 .  00000
     7.00        13 .  0000000
     2.00        14 .  00
     1.00        15 .  0
     2.00        16 .  00
     3.00        17 .  000

 Stem width:      1.00
 Each leaf:        1 case(s)
```







Nonparametric Correlations

Notes

Output Created		05-JUN-2023 13:10:47
Comments		
Input	Data	D:\Office\Statistics\Data dr Rahmat.sav
	Active Dataset	DataSet25
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	36
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each pair of variables are based on all the cases with valid data for that pair.
Syntax		NONPAR CORR /VARIABLES=Tib_Amp_Kanan Tib_Amp_Kiri Sur_Amp_Kanan Sur_Amp_Kiri Total /PRINT=SPEARMAN TWOTAIL NOSIG /MISSING=PAIRWISE.
Resources	Processor Time	00:00:00.00
	Elapsed Time	00:00:00.00
	Number of Cases Allowed	393216 cases[a]

a. Based on availability of workspace memory

Correlations

			Tib_Amp_Kanan	Tib_Amp_Kiri	Sur_Amp_Kanan	Sur_Amp_Kiri	Total
Spearman's rho	Tib_Amp_Kanan	Correlation Coefficient	1.000	.761**	.463**	.410*	-.342*
		Sig. (2-tailed)	.	.000	.004	.013	.041
		N	36	36	36	36	36
	Tib_Amp_Kiri	Correlation Coefficient	.761**	1.000	.460**	.478**	-.312
		Sig. (2-tailed)	.000	.	.005	.003	.064
		N	36	36	36	36	36
	Sur_Amp_Kanan	Correlation Coefficient	.463**	.460**	1.000	.844**	-.373*
		Sig. (2-tailed)	.004	.005	.	.000	.025
		N	36	36	36	36	36
	Sur_Amp_Kiri	Correlation Coefficient	.410*	.478**	.844**	1.000	-.526**
		Sig. (2-tailed)	.013	.003	.000	.	.001
		N	36	36	36	36	36
	Total	Correlation Coefficient	-.342*	-.312	-.373*	-.526**	1.000
		Sig. (2-tailed)	.041	.064	.025	.001	.
		N	36	36	36	36	36

**. Correlation is significant at the 0.01 level (2-tailed).

*. Correlation is significant at the 0.05 level (2-tailed).

Means

Notes

Output Created		05-JUN-2023 13:11:12
Comments		
Input	Data	D:\Office\Statistics\Data dr Rahmat.sav
	Active Dataset	DataSet25
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	36
Missing Value Handling	Definition of Missing	For each dependent variable in a table, user-defined missing values for the dependent and all grouping variables are treated as missing.
	Cases Used	Cases used for each table have no missing values in any independent variable, and not all dependent variables have missing values.
Syntax		MEANS TABLES=Tib_Amp_Kanan Tib_Amp_Kiri Sur_Amp_Kanan Sur_Amp_Kiri BY Kategori /CELLS=MEAN STDDEV MEDIAN MIN MAX.
Resources	Processor Time	00:00:00.03
	Elapsed Time	00:00:00.00

Case Processing Summary

	Cases					
	Included		Excluded		Total	
	N	Percent	N	Percent	N	Percent
Tib_Amp_Kanan * Kategori	36	100.0%	0	0.0%	36	100.0%
Tib_Amp_Kiri * Kategori	36	100.0%	0	0.0%	36	100.0%
Sur_Amp_Kanan * Kategori	36	100.0%	0	0.0%	36	100.0%
Sur_Amp_Kiri * Kategori	36	100.0%	0	0.0%	36	100.0%

Report

Kategori		Tib_Amp_Kanan	Tib_Amp_Kiri	Sur_Amp_Kanan	Sur_Amp_Kiri
No Neuropath	Mean	8.2000	9.9667	19.6333	30.3667
	Std. Deviation	1.00000	3.06159	21.10979	33.38298
	Median	8.2000	8.3000	11.5000	12.0000
	Minimum	7.20	8.10	3.80	10.20
	Maximum	9.20	13.50	43.60	68.90
Mild	Mean	9.5000	9.4000	13.2000	16.4000
	Std. Deviation	.	.	.	.
	Median	9.5000	9.4000	13.2000	16.4000
	Minimum	9.50	9.40	13.20	16.40
	Maximum	9.50	9.40	13.20	16.40
Moderate	Mean	8.8250	8.9667	4.8667	5.0417
	Std. Deviation	5.82598	4.90071	5.58347	4.99463
	Median	8.1000	8.8500	4.3000	4.8500
	Minimum	.20	.10	.00	.00
	Maximum	20.20	18.60	18.10	17.80
Severe	Mean	6.6800	7.7850	5.5500	6.1350
	Std. Deviation	4.08677	4.62286	5.44412	8.96369
	Median	7.0000	7.0000	5.9500	2.7000
	Minimum	.00	.00	.00	.00
	Maximum	16.20	16.10	16.90	36.10
Total	Mean	7.6000	8.4056	6.7083	8.0750

	Std. Deviation	4.57421	4.50003	8.29483	12.84591
	Median	7.8500	8.4000	6.5500	4.8500
	Minimum	.00	.00	.00	.00
	Maximum	20.20	18.60	43.60	68.90

Oneway

Notes

Output Created		05-JUN-2023 13:11:25
Comments		
Input	Data	D:\Office\Statistics\Data dr Rahmat.sav
	Active Dataset	DataSet25
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	36
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each analysis are based on cases with no missing data for any variable in the analysis.
Syntax		ONEWAY Tib_Amp_Kanan Tib_Amp_Kiri BY Kategori /MISSING ANALYSIS.
Resources	Processor Time	00:00:00.00
	Elapsed Time	00:00:00.01

ANOVA

		Sum of Squares	df	Mean Square	F	Sig.
Tib_Amp_Kanan	Between Groups	39.625	3	13.208	.610	.613
	Within Groups	692.695	32	21.647		
	Total	732.320	35			
Tib_Amp_Kiri	Between Groups	19.780	3	6.593	.306	.821
	Within Groups	688.979	32	21.531		
	Total	708.759	35			

NPar Tests

Notes

Output Created		05-JUN-2023 13:11:51
Comments		
Input	Data	D:\Office\Statistics\Data dr Rahmat.sav
	Active Dataset	DataSet25
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	36
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each test are based on all cases with valid data for the variable(s) used in that test.
Syntax		NPAR TESTS /K-W=Sur_Amp_Kanan Sur_Amp_Kiri BY Kategori(1 4) /MISSING ANALYSIS.
Resources	Processor Time	00:00:00.00
	Elapsed Time	00:00:00.00
	Number of Cases Allowed[a]	393216

a. Based on availability of workspace memory.

Kruskal-Wallis Test

Ranks

	Kategori	N	Mean Rank
Sur_Amp_Kanan	No Neuropath	3	27.17
	Mild	1	32.00
	Moderate	12	16.29
	Severe	20	17.85
	Total	36	
Sur_Amp_Kiri	No Neuropath	3	31.00
	Mild	1	32.00
	Moderate	12	17.58
	Severe	20	16.50
	Total	36	

Test Statistics[a,b]

	Sur_Amp_Kanan	Sur_Amp_Kiri
Kruskal-Wallis H	4.440	6.873
df	3	3
Asymp. Sig.	.218	.076

a. Kruskal Wallis Test

b. Grouping Variable: Kategori